Publication | Closed Access

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

Anti-tigit AntibodyMedicineImmunologyTherapeutic EfficacyImmune Checkpoint InhibitorAnti-pd-1/pd-l1-refractory NsclcPharmacotherapyImmunotherapyOncologyNovel Therapy